Table 1.
Comparison of clinical features between the EF recovery group and the no EF recovery group at 1 year after RARP.
| Features | No EF recovered at 1 year Median (IQR) / Count (%) (N = 46) |
EF recovered at 1 year Median (IQR) / Count (%) (N = 34) |
p-value |
|---|---|---|---|
| Patient factors | |||
| Age, year | 65 (61–69) | 61 (58–65) | 0.02 |
| BMI, kg/m2 | 27.4 (25.9–29.0) | 28.7 (25.3–30.1) | 0.69 |
| Pre-op SHIM score | 24 (21–25) | 24 (22–25) | 0.36 |
| PSA, ng/mL | 6.8 (5.4–11.2) | 7.7 (5.2–9.8) | 0.74 |
| ASA | 0.03 | ||
| I | 3 (6.5%) | 8 (23.5%) | |
| ≥II | 43 (93.5%) | 26 (76.5%) | |
| Pre-op Gleason score | 0.22 | ||
| 6 (ISUP 1) | 12 (26.1%) | 8 (23.5%) | |
| 7 (ISUP 2/3) | 22 (47.8%) | 22 (64.7%) | |
| ≥8 (ISUP 4/5) | 12 (26.1%) | 4 (11.8%) | |
| Post-op Gleason score | 0.19 | ||
| 6 (ISUP 1) | 4 (8,7%) | 6 (17.6%) | |
| 7 (ISUP 2/3) | 32 (69.6%) | 25 (73.5%) | |
| ≥8 (ISUP 4/5) | 10 (21.7%) | 3 (8.8%) | |
| Pathological tumor stage | 0.65 | ||
| pT2 | 22 (47.8%) | 18 (52.9%) | |
| ≥pT3 | 24 (52.2%) | 16 (47.1%) | |
| Prostate volume, g | 48 (34–54) | 39 (32–56) | 0.35 |
| Treatment factors | |||
| Nerve-sparing extent | 0.49 | ||
| Partial | 14 (30.4%) | 8 (23.5%) | |
| Full | 32 (69.6%) | 26 (76.5%) | |
Continuous variables were compared by Mann–Whitney U test and reported as median (IQR). Categorical variables were compared by Chi-square test or Fisher exact test as indicated.
ASA American Society of Anesthesiology physical status classification system, BMI body mass index, IQR interquartile range, SHIM Sexual Health Inventory for Men, ISUP International Society of Urological Pathology, PSA prostate specific antigen.